Can rheumatoid arthritis go into remission without any medication?
The short answer is: it is very unlikely. Rheumatoid arthritis is a chronic autoimmune disease that, left untreated, typically leads to progressive joint damage and disability [6]. The research reviewed here focuses overwhelmingly on remission achieved through medication, not spontaneous remission. In large clinical trials, remission rates at 6 months were only 14.8% to 20.6% in early RA and 4.2% to 6.0% in established RA, and all patients in those trials were receiving treatment (either methotrexate, a biologic, or a placebo) [1]. This shows that even with treatment, remission is not guaranteed, and without treatment, the odds are far lower.
One study specifically looked at patients who achieved drug-free remission after stopping their medication [5]. This was an experimental medicine study where patients in stable remission on medication had their drugs withdrawn to study flare-ups. While some patients did remain in remission off medication, the study was designed to understand flare biology, not to measure how often drug-free remission occurs. The key takeaway is that drug-free remission is possible but is the exception, not the rule, and it is most often seen in patients who had already achieved deep remission on medication first [5][6].
If I achieve remission on medication, what predicts staying in remission?
Even when remission is achieved with medication, staying in remission long-term is not guaranteed. Two large cohort studies found that about 53-57% of patients who were in remission at one annual checkup remained in remission for the next two years [4]. The strongest predictors of staying in remission were: having RA for less than 5 years, having no physical disability (a score of 0 on a disability questionnaire), and not taking oral steroids (glucocorticoids) [4]. This means that early, effective treatment that avoids steroids gives the best chance of sustained remission.
Another study of patients on biologic DMARDs who achieved remission found that stopping glucocorticoids and continuing methotrexate were independently associated with much longer drug survival [7]. Specifically, patients who stopped steroids had a 69% lower risk of their biologic failing, and those who stayed on methotrexate had a 66% lower risk [7]. This reinforces that steroids, while helpful short-term, may undermine long-term remission, and that combination therapy (biologic + methotrexate) is more durable than biologic alone.
What does 'remission' actually mean, and can you have it without knowing it?
Remission is not just feeling better; it is a strict clinical definition. The American College of Rheumatology and EULAR define remission using criteria like the Boolean 2.0, which requires a tender joint count, swollen joint count, and patient global assessment all to be low (e.g., patient global assessment ≤2 on a 0-10 scale) [1]. These criteria are important because they predict good long-term outcomes like preserved physical function and no joint damage progression [1]. However, even when these clinical criteria are met, ultrasound can detect ongoing inflammation (power Doppler signals) in over half of patients [3]. This means that 'clinical remission' does not always mean 'biological remission' — silent inflammation can persist.
This is a crucial caveat for anyone hoping to stop medication. If you feel fine but have subclinical inflammation on ultrasound, stopping treatment could lead to a flare and joint damage. The study on drug withdrawal found that specific immune cells (certain T cells and B cells) become activated weeks before a flare is clinically apparent [5]. So, remission without medication is a high-stakes gamble: you might feel well, but your immune system may be primed to attack your joints again. Regular monitoring and shared decision-making with your rheumatologist are essential.
About These Sources
This answer is built on 7 peer-reviewed studies — published from 2019 to 2024, 1 from 2024 or later, 3 in Q1 journals, collectively cited 753 times — selected as the most relevant from 8 studies that passed quality screening, drawn from 57 papers retrieved from a database of over 500 million.
Sources used in this answer
American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision
In a large analysis of 2,048 trial participants, remission rates at 6 months on treatment were 14.8-20.6% in early RA and 4.2-6.0% in established RA, using the updated Boolean 2.0 criteria [1].
The Economic Benefit of Remission for Patients with Rheumatoid Arthritis
In a real-world study of 2,339 RA patients, those in remission had significantly lower annual healthcare costs ($40,072) compared to those with moderate ($56,536) or high disease activity ($59,217) [2].
Validity of Remission Criteria in Rheumatoid Arthritis Compared to Ultrasound-Defined Remission.
Among 30 RA patients in clinical remission by DAS28, ultrasound (power Doppler) detected ongoing synovial inflammation in 57% of cases, showing that clinical remission often hides subclinical disease activity [3].
Prevalence and predictors for sustained remission in rheumatoid arthritis.
In two large cohorts (total 465 patients in remission), 53-57% sustained remission for 2 years; predictors were disease duration <5 years, no disability, and no oral glucocorticoid use [4].
Single-cell insights into immune dysregulation in rheumatoid arthritis flare versus drug-free remission
In an experimental drug-withdrawal study, specific T and B cell subsets were identified that herald flare weeks before clinical symptoms, suggesting immune dysregulation persists even in drug-free remission [5].
The pathogenesis of rheumatoid arthritis
RA is a lifelong disease without a cure; current treatments can induce remission but rarely achieve immune homeostasis or drug-free remission, and tissue repair remains an unmet need [7].
Predictors of long-term clinical remission in rheumatoid arthritis.
Among 86 RA patients who achieved SDAI remission on a first biologic, stopping glucocorticoids (HR 0.31) and continuing methotrexate (HR 0.34) were independently associated with longer drug survival [8].